204 related articles for article (PubMed ID: 34680248)
1. Impact of Epithelial-Mesenchymal Transition on the Immune Landscape in Breast Cancer.
Khadri FZ; Issac MSM; Gaboury LA
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680248
[TBL] [Abstract][Full Text] [Related]
2. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
3. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
5. Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Akrida I; Nikou S; Gyftopoulos K; Argentou M; Kounelis S; Zolota V; Bravou V; Papadaki H
Histol Histopathol; 2018 Sep; 33(9):937-949. PubMed ID: 29608014
[TBL] [Abstract][Full Text] [Related]
6. GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition.
Yang Z; Wu D; Chen Y; Min Z; Quan Y
Cancer Biol Ther; 2019; 20(9):1195-1205. PubMed ID: 31063022
[TBL] [Abstract][Full Text] [Related]
7. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
[TBL] [Abstract][Full Text] [Related]
8. Nanochip-Induced Epithelial-to-Mesenchymal Transition: Impact of Physical Microenvironment on Cancer Metastasis.
Dhawan U; Sue MW; Lan KC; Buddhakosai W; Huang PH; Chen YC; Chen PC; Chen WL
ACS Appl Mater Interfaces; 2018 Apr; 10(14):11474-11485. PubMed ID: 29557633
[TBL] [Abstract][Full Text] [Related]
9. Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma.
Cao YW; Wan GX; Sun JP; Cui XB; Hu JM; Liang WH; Zheng YQ; Li WQ; Li F
Kaohsiung J Med Sci; 2015 Feb; 31(2):70-6. PubMed ID: 25645984
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
Singh R; Singh UP; Agrawal V; Garg M
Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
[TBL] [Abstract][Full Text] [Related]
11. GRHL2 Acts as an Anti-Oncogene in Bladder Cancer by Regulating ZEB1 in Epithelial-Mesenchymal Transition (EMT) Process.
Shen J; Lv X; Zhang L
Onco Targets Ther; 2020; 13():2511-2522. PubMed ID: 32280236
[TBL] [Abstract][Full Text] [Related]
12. The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.
Mooney SM; Talebian V; Jolly MK; Jia D; Gromala M; Levine H; McConkey BJ
J Cell Biochem; 2017 Sep; 118(9):2559-2570. PubMed ID: 28266048
[TBL] [Abstract][Full Text] [Related]
13. Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.
Singh R; Mandhani A; Agrawal V; Garg M
Cancer Microenviron; 2018 Jun; 11(1):23-39. PubMed ID: 29349669
[TBL] [Abstract][Full Text] [Related]
14. Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer.
Markiewicz A; Ahrends T; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Jaśkiewicz J; Szade J; Biernat W; Zaczek AJ
J Transl Med; 2012 Nov; 10():226. PubMed ID: 23157797
[TBL] [Abstract][Full Text] [Related]
15. Epithelial cell adhesion molecule and epithelial-mesenchymal transition are associated with vasculogenic mimicry, poor prognosis, and metastasis of triple negative breast cancer.
Wu Q; Wang J; Liu Y; Gong X
Int J Clin Exp Pathol; 2019; 12(5):1678-1689. PubMed ID: 31933986
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.
Rosivatz E; Becker I; Specht K; Fricke E; Luber B; Busch R; Höfler H; Becker KF
Am J Pathol; 2002 Nov; 161(5):1881-91. PubMed ID: 12414534
[TBL] [Abstract][Full Text] [Related]
17. Expression and significance of c-kit and epithelial-mesenchymal transition (EMT) molecules in thymic epithelial tumors (TETs).
Wu Z; Xue S; Zheng B; Ye R; Xu G; Zhang S; Zeng T; Zheng W; Chen C
J Thorac Dis; 2019 Nov; 11(11):4602-4612. PubMed ID: 31903249
[TBL] [Abstract][Full Text] [Related]
18. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.
Aleskandarany MA; Negm OH; Green AR; Ahmed MA; Nolan CC; Tighe PJ; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):339-48. PubMed ID: 24771047
[TBL] [Abstract][Full Text] [Related]
19. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
[TBL] [Abstract][Full Text] [Related]
20. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
